Continued positive efficacy and durability with stable visual acuity (VA) and optical coherence tomography (OCT) through eight-month follow-up
- 41% of eyes remained rescue free up to nine months after a single dose of EYP-1901
- Positive safety data continued with no dose limiting toxicities, no ocular serious adverse events (SAEs) and no drug-related systemic SAEs observed
- Overall treatment burden reduced by 75% at eight months
- Phase 2 studies for EYP-1901 in wet AMD expected to initiate in Q3 2022 and in diabetic retinopathy in 2H 2022
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced updated interim data from the "Durasert® and Vorolanib in Ophthalmology" (DAVIO) Phase 1 clinical trial of EYP-1901, a bioerodible sustained delivery intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment targeting wet age-related macular degeneration (wet AMD). These data are being presented today at the Angiogenesis, Exudation, and Degeneration 2022 virtual meeting by Jay S. Duker, M.D., Chief Operating Officer, EyePoint Pharmaceuticals.
https://finance.yahoo.com/news/eyepoint-pharmaceuticals-announces-updated-positive-131000570.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.